Biodefense industrial complex

After the 2001 anthrax letters and Project BioShield, U.S. biodefense funding and classified programs produced a sprawling network of high‑containment labs and private contractors, with rapid growth in BSL‑3/4 capacity and little public oversight. That concentration shifted scientific power toward secretive biosecurity programs and normalized risky research framings like 'gain‑of‑function' without transparent governance. — This frames a durable governance problem: large, opaque biodefense capacity raises accident, attribution, and policy‑capture risks that deserve public debate and regulatory fixes.